Malaria, Falciparum
Conditions
Keywords
antimalarials
Brief summary
Sulfadoxine-pyrimethamine (SP) is the current first-line treatment for uncomplicated malaria in Malawi. The malaria parasite P. falciparum has developed resistance to this drug so that the drug is much less effective than in previous years. This study was developed and conducted in collaboration with the National Malaria Control Programme of Malawi to assess the efficacy of four antimalarial drug combinations to provide evidence to assist the Malawian Ministry of Health in identifying and implementing as policy the next first-line antimalarial for uncomplicated malaria in Malawi. In an open, randomized trial in children under five years of age, four drug combinations, all of which are licensed in Malawi, are being assessed: amodiaquine plus sulfadoxine-pyrimethamine (AQ-SP), amodiaquine plus artesunate (AQ-Art), chlorproguanil-dapsone plus artesunate (CD-Art) and lumefantrine-artemether (LA). SP is also included as a fifth arm of the study for current data on its efficacy. Data on side effects of the drugs will also be collected. The results of this study will provide some of the information necessary to guide the Malawi National Malaria Control Program in selecting its next first antimalarial treatment for uncomplicated malaria. The study adheres to the World Health Organization's 2003 standardized protocol for assessing antimalarial drug efficacy.
Interventions
DRUGsulfadoxine-pyrimethamine
DRUGamodiaquine plus sulfadoxine-pyrimethamine
DRUGlumefantrine-artemether
Sponsors
Ministry of Health and Population, Malawi
Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 59 Months
Healthy volunteers
No
Inclusion criteria
* Children age 6 - 59 months * Axillary temperature ≥ 37.5 °C * Monoinfection with P. falciparum * Parasitaemia between 2000 - 200000 parasites/µl * Haemoglobin concentration (finger-prick blood sample by HemoCue) \> 7g/dl * Consent by the patient's adult guardian * Residence in the locality and willingness to attend for scheduled visits
Exclusion criteria
* altered consciousness * convulsions * prostration (inability to sit/stand/suck/drink) * respiratory distress or breathlessness * jaundice * abnormal breathing * haemoglobinuria * circulatory collapse * persistent vomiting (cannot keep down liquids) * evidence of a diagnosis other than malaria on physical examination * presence of mixed infection * presence of severe malnutrition (as evidenced by symmetrical oedema involving at least the feet, light hair color, or cachexia) * contraindications to the antimalarial drugs used, especially history of allergy * history of receiving a drug with antimalarial activity in the week prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Rate of Adequate Clinical and Parasitological Response at 14 days (WHO-defined measure of efficacy) | — |
Secondary
| Measure | Time frame |
|---|---|
| • Mean percent change in blood haemoglobin concentration between day 0 and day 28 | — |
| • Incidence of adverse events during the period of observation | — |
| • Rate of Early Treatment Failure (as defined by the WHO in their 2003 standardized protocol for assessing antimalarial drug efficacy) | — |
| • Rate of Late Clinical Failure (as defined by the WHO) | — |
| • Rate of Late Parasitologic Failure (as defined by the WHO) | — |
| • Rate of Adequate clinical and parasitological response 28 days | — |
| • Percent of patients with a decrease in haemoglobin concentration of ≥ 2g/dl | — |
| • Prevalence of parasitemia on Day 2 | — |
| • Prevalence of parasitemia on Day 3 | — |
| • Gametocyte prevalence on Day 14 | — |
| • Gametocyte prevalence on Day 28 | — |
| • Percent of patients with a decrease in haemoglobin concentration | — |
Countries
Malawi
Outcome results
None listed